Journal of Acute Care

Register      Login

VOLUME 1 , ISSUE 2 ( May-August, 2022 ) > List of Articles


Hemoadsorption (CytoSorb®) in Management of Cytokine Storm and Implication in COVID-19 Pandemic

Harish M Maheshwarappa, Shreedhar S Joshi, Robert James Premkumar, Shivangi Mishra, Shiva Prasad

Keywords : Blood filtration, Coronavirus disease 2019, Cytokine storm, CytoSorb®, Hemoadsorption

Citation Information : Maheshwarappa HM, Joshi SS, Premkumar RJ, Mishra S, Prasad S. Hemoadsorption (CytoSorb®) in Management of Cytokine Storm and Implication in COVID-19 Pandemic. 2022; 1 (2):61-67.

DOI: 10.5005/jp-journals-10089-0019

License: CC BY-NC 4.0

Published Online: 31-12-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Introduction: Sepsis-related deaths contribute up to 20% of all global deaths, with the highest-burden from sub-Saharan Africa and Southeast Asia. Cytokines are the mediators of organ dysfunction in systemic inflammatory response syndrome (SIRS) across varied etiologies, including sepsis. The imbalance of pro-and anti-inflammatory cytokines continues to be the crux of the pathophysiology of organ dysfunction in septic shock. Therapies to treat cytokines either by antagonizing them or filtering them out of the body are evolving. Hemoadsorption is a process of filtering out cytokines and other metabolites involved in SIRS by surface adsorption. Materials and methods: We searched for terms–Hemoadsorption, CytoSorb, in PubMed and Google Scholar. We enrolled manuscripts with patients at Indian Centers for review. We extend our review of cytokine storm in COVID-19 and the utility of CytoSorb as an adjuvant in the management of septic shock in COVID-19. Conclusion: Severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2) infection causing COVID-19 (Coronavirus disease - 2019) pandemic has affirmed cytokine storm as the principal pathology causing morbidity and mortality. Management strategies are mostly supportive since specific antiviral therapy is still in the incipient stage. Cytokine adsorption is being used across most Western countries in COVID-19 septic shock. COVID-19 with cytokine storm as its main pathology is a suitable substrate for the use of CytoSorb. COVID-19 patients with elevated cytokine levels can be offered CytoSorb® hemoadsorption along with other supportive therapies.

  1. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet 2020;395(10219):200–211. DOI: 10.1016/S0140-6736(19)32989-7
  2. Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets–an updated view. Mediators Inflamm 2013;2013(6):165974. DOI: 10.1155/2013/165974
  3. Tisoncik JR, Korth MJ, Simmons CP, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012;76(1):16–32. DOI: 10.1128/MMBR.05015-11
  4. Beutel G, Wiesner O, Eder M, et al. Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care 2011;15(2):R80. DOI: 10.1186/cc10073
  5. Park WY, Goodman RB, Steinberg KP, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164(10 Pt 1):1896–1903. DOI: 10.1164/ajrccm.164.10.2104013
  6. Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol 2019;10:55. DOI: 10.3389/fimmu.2019.00055
  7. Seguin A, Galicier L, Boutboul D, et al. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest 2016;149(5):1294–1301. DOI: 10.1016/j.chest.2015.11.004
  8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5
  9. La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019;133(23):2465–2477. DOI: 10.1182/blood.2018894618
  10. Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003;27(9):792–801. DOI: 10.1046/j.1525-1594.2003.07289.x
  11. Greil C, Roether F, La Rosée P, et al. Rescue of cytokine storm due to HLH by hemoadsorption in a ctla4-deficient patient. J Clin Immunol 2017;37(3)273–276. DOI: 10.1007/s10875-017-0377-7
  12. Bottari G, Guzzo I, Marano M, et al. Hemoperfusion with cytosorb in pediatric patients with septic shock: a retrospective observational study. Int J Artif Organs 2020;43(9):587–593. DOI: 10.1177/0391398820902469
  13. Therapeutic effects | CytoSorbents Europe GmbH n.d. [Internet]. Available from:
  14. Morris C, Gray L, Giovannelli M. Early report: the use of CytosorbTM haemabsorption column as an adjunct in managing severe sepsis: initial experiences, review and recommendations. J Intensive Care Soc 2015;16(3):257–264. DOI: 10.1177/1751143715574855
  15. Ankawi G, Xie Y, Yang B, et al. What have we learned about the use of cytosorb adsorption columns? Blood Purif 2019;48(3):196–202. DOI: 10.1159/000500013
  16. Mair H, Jilek C, Haas B, et al. Ticagrelor and rivaroxaban elimination with cytosorb adsorber before urgent off-pump coronary bypass. Ann Thorac Surg 2020;110(5):e369–e370. DOI: 10.1016/j.athoracsur.2020.03.108
  17. Kutnik P, Borys M. Applications of Cytosorb in clinical practice. J Pre-Clin Clin Res 2019;13(4):162–166. DOI: 10.26444/jpccr/112882
  18. Kogelmann K, Jarczak D, Scheller M, et al. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care 2017;21(1):74. DOI: 10.1186/s13054-017-1662-9
  19. Basu R, Pathak S, Goyal J, et al. Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: a case study. Indian J Crit Care Med 2014;18(12):822–824. DOI: 10.4103/0972-5229.146321
  20. Ticagrelor CytoSorb Hemoadsorption - Full Text View - Clinical. Ticagrelor CytoSorb Hemoadsorption - Full Text View - n.d. [Internet]. Available from:
  21. CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery - Full Text View - n.d. [Internet]. Available from:
  22. Cytosorb Therapy in Cardiac Surgery -Full Text View - n.d. [Internet]. Available from:
  23. Hawchar F, László I, Öveges N, et al. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care 2019;49:172–178. DOI: 10.1016/j.jcrc.2018.11.003
  24. Bateman RM, Sharpe MD, Jagger JE, et al. 36th International Symposium on intensive care and emergency medicine: Brussels, Belgium. Crit Care 2016;20(2):94. DOI: 10.1186/s13054-016-1208-6
  25. Evaluating a CytoSorb Score in Septic Shock - Full Text View - n.d. [Internet]. Available from:
  26. Mehta Y, Mehta C, Kumar A, et al. Experience with hemoadsorption (CytoSorb®) in the management of septic shock patients. World J Crit Care Med 2020;9:1-12.
  27. Singh A, Mehta Y, Trehan N. Bilirubin removal using cytoSorb filter in a cardiac surgical patient. J Cardiothorac Vasc Anesth 2019;33:881-883.
  28. Surendra M, Cherukuri B, Kumar S, et al. A Retrospective analysis of efficacy of hemoadsorption (CYTOSORB) in refractory septic shock patients as an adjuvant. Int J Sci Res 2019;8(10).
  29. Paul R, Sathe P, Kumar S, et al. Multicentered prospective investigator initiated study to evaluate the clinical outcomes with extracorporeal cyto-kine adsorption device (CytoSorb®) in patients with sepsis and septic shock. World J Crit Care Med. 2021;10(1):22-34.
  30. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet Lond Engl 2020;395(10229):1033-1034.
  31. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hos-pitalized patients with 2019 novel coronavirus - infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061.
  32. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46(5):846-848.
  33. Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor sys-tem. Cytokine Growth Factor Rev 2020;53:25-32.
  34. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020;8:e46-7.
  35. Pancani F, Pavani R, Quacquarelli A, et al. Successful use of CytoSorb in a Covid-19 patient with secondary septic shock due to a sacral decubitus infection. Int J Artif Or-gans 2021;44(12):1034-1038.
  36. Yang X-H, Sun R-H, Zhao M-Y, et al. Expert recommen-dations on blood purification treatment protocol for patients with severe COVID-19. Chronic Dis Transl Med 2020;6(2):106-114.
  37. CytoSorb ® 300 mL Device authorized by FDA for emergency treatment of COVID-19. n.d. [Internet]. Available from:
  38. Hong X, Xiong J, Feng Z, et al. Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19? Int J Infect Dis 2020;94:78-80.
  39. Zeng Y, Cai Z, Xianyu Y, et al. Prognosis when using extracorpo-real membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series. Crit Care Lond Engl 2020 15;24(1):148.
  40. Alberici F, Delbarba E, Manenti C, et al. Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy. Kidney Int Rep 2020;5:580 -585.
  41. Asociación Panameña de Medicina Criticay TerapiaIntensiva, GUÍASNACIONALESDE ATENCIóN DE PACIENTES ADULTOS COVID-19 VERSION 2.0,
  42. CytoSorb, the Wuhan Coronavirus, and Cytokine Storm n.d. [Internet]. Available from:
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.